Introduction {#Sec1}
============

Worldwide, breast cancer is the most common female cancer and the most common cause of female cancer-related death \[[@CR1]\]. Breast cancer is a heterogeneous disease defined by various molecular subtypes, each one with an associated risk profile and treatment recommendations \[[@CR2], [@CR3]\]. Several loci of high, moderate, and low penetrance have been implicated in inherited risk of breast cancer \[[@CR4], [@CR5]\]. The genetic predisposition to breast cancer can be described as a continuum from a strong genetic contribution to a weaker polygenic genetic contribution with an environmental component.

Over 20 years ago, the *BRCA1* and *BRCA2* genes were identified as highly penetrant susceptibility genes for hereditary breast and ovarian cancers \[[@CR6], [@CR7]\]. Inactivating variants in those tumor suppressors account for approximately 16 % of the familial risk of breast cancer \[[@CR8]\] and represent 5--10 % of all breast cancers \[[@CR9]\]. Women carrying a *BRCA* mutation are estimated to have a cumulative cancer risk by age of 70 years of up to 87 and 54 % for breast and ovarian cancer, respectively \[[@CR10]--[@CR16]\]. They also have modest to marked increases in the lifetime risk of developing other cancer types such as colorectal, gastric, gallbladder and bile duct, malignant melanoma, pancreatic, prostate, and uterine cancers \[[@CR10], [@CR14], [@CR16], [@CR17]\]. The early identification of individuals at risk by genetic testing has been shown to be associated with increased surveillance and risk-reduction strategies ultimately leading to diagnosis of early stage tumors and improved outcomes \[[@CR18], [@CR19]\]. However, effective identification of *BRCA1*/*2* mutation carriers depends on the availability and access to genetic counseling and testing of at-risk individuals.

A significant portion of populations inhabiting Central and South America as well as certain islands of the Caribbean share an official language derived from Latin, majorly Spanish or Portuguese. Despite this common heritage from the colonization era, each region of Latin America and the Caribbean (hereby referred to as Latin America) is often characterized by unique geography, culture, politics, and socioeconomic factors \[[@CR20]\]. In the USA, Hispanics (defined by the U.S. Census Bureau a person of Cuban, Mexican, Puerto Rican, South or Central American---except for Brazil, or other Spanish culture or origin regardless of race) make up 16.3 % of the population and accounted for 56 % of the national population growth between 2000 and 2010, which makes this group the fastest growing minority in the country \[[@CR21]\].

Despite lower incidence of breast cancer in Latin America populations when compared to Europe or the USA, the mortality-to-incidence ratio is significantly higher in the former region \[[@CR21], [@CR22]\]. This is in part due to poor access to cancer care and presentation at later stages \[[@CR22]\]. For instance, it is estimated that 58 % of the breast cancers in Mexico are detected at stage III--IV \[[@CR23]\]. In this population, the high cost associated with cancer care was attributed to late diagnosis, suggesting a need for the implementation of better prevention and detection strategies \[[@CR24]\]. However, in several regions of Latin America, genetic testing is either not available or the associated cost is still prohibitive for a large proportion of individuals at risk \[[@CR22]\].

There is limited information available regarding population-specific risks and very few systematic studies of the prevalence of genetic variants predisposing to breast cancer relevant to the populations of Latin America. Here we review the current knowledge about *BRCA1* and *BRCA2* variants in women from Latin America, the Caribbean, and Hispanics in the United States with the objective of identifying areas in need of further research and avenues for improving access to genetic testing for hereditary cancers.

The *BRCA1* and *BRCA2* mutation spectrum in Latin America {#Sec2}
----------------------------------------------------------

In recent years, increasing accessibility of next-generation sequencing (NGS) has resulted in its increased use in clinical genetic testing \[[@CR25]\]. NGS approaches allows the cost-effective interrogation of multiple targets and has driven the expansion from *BRCA1* and *BRCA2* testing to the so-called 'panel testing,' in which a number of additional high- and moderate-penetrance hereditary cancer genes (demonstrated and suspected) are included \[[@CR26]\]. Despite these advances, the cost of comprehensive *BRCA1* and *BRCA2* analysis is still prohibitive for low income individuals in these countries. Importantly, although the technical sensitivity of these assays is very high and virtually all variants can be accurately detected, our ability to clinically annotate these variants has lagged.

As a solution, amplicon-based single-site panels of recurrent Latin American *BRCA* pathogenic variants that would constitute the first line of screening of at-risk individuals prior to performing comprehensive *BRCA* analysis have been developed. Such model of tiered testing has been widely successful in the Ashkenazi Jewish population in which three common pathogenic variants explain 78.4 % of the cases \[[@CR27]\]. The development of a clinically useful panel in Latin America will require knowledge of the pathogenic variant spectrum in each region or country and depend on the presence of recurrent variants explaining a majority of the hereditary breast and ovarian cancer cases.

To provide a comprehensive picture we have conducted a literature review of the *BRCA1* and *BRCA2* variants identified in Latin America (Supplementary Fig. 1). Between 1994 and August 2015, 33 publications reported *BRCA* variants in populations from 13 countries of Central and South America, the Caribbean, and Hispanic/Latino populations from the US. Taken together, these studies have screened a total of 4835 individuals and identified 167 different pathogenic variants (Supplementary Table [1](#Tab1){ref-type="table"}). Table [1](#Tab1){ref-type="table"} summarizes the characteristics of the cohorts, the prevalence of the *BRCA* variants reported, and screening methods for each of the study reviewed.Table 1Characteristics of the cohorts and *BRCA1* and *BRCA2* mutation prevalence from 27 publications in 13 countries of Latin America and the CaribbeanCountryCohort sizeCohort typePrevalenceBRCA screening methodsLarge rearrangements screeningReferenceArgentina94BC and/or OC cases, with early onset no FH (*n* = 37); BC and/or OC cases with onset at any age and FH (BC, OC) (*n* = 57)16.2--35.8Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsn/aSolano et al. \[[@CR67]\]Argentina40BC and/or OC cases of Ashkenazi Jewish origin with FH (BC, OC)35.7--58.3Screening for three founder Ashkenazi Jewish mutationsn/aSolano et al. \[[@CR67]\]Bahamas204Unselected invasive BC cases27.1Screening for six *BRCA1* African-American founder mutations, direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsMLPA panelDonenberg et al. \[[@CR42]\], Akbari et al. \[[@CR41]\]Brazil31BC cases selected for early onset, bilaterality and/or FH (BC, OC, male BC)12.9*BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by SSCP, confirmation of the variants by direct sequencingn/aDufloth et al. \[[@CR44]\]Brazil402Unselected invasive BC cases2.3Screening for three founder Ashkenazi Jewish mutations using FMPA, *BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by PTT, DGGE, DHPLC, confirmation of the variants by direct sequencing*BRCA1* exon 13 6 kb duplicationGomes et al. \[[@CR33]\]Brazil612Index cases from families with history of BC and/or OC3.4*BRCA1* exon 11 and *BRCA2* exon 10 and 11 screening by PTT, confirmation of the variants by direct sequencingn/aEsteves et al. \[[@CR45]\]Brazil137Personal and/or FH suggestive of HBOC5.1Screening for three founder Ashkenazi Jewish mutations by direct sequencingn/aEwald et al. \[[@CR46]\]Brazil106Personal and/or FH suggestive of HBOC8.5*BRCA1* coding exons and intron/exon junctions screening by SSCP, confirmation of the variants by direct sequencing; *BRCA2* two mutations paneln/aFelix et al. \[[@CR47]\]Brazil120Personal and/or FH suggestive of HBOC22.5Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsMLPA panelSilva et al. \[[@CR48]\]Chile54BC and/or OC cases with FH (BC, OC, other cancers)20.4*BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by HDA, PTT, SSCP, and confirmation of the variants by direct sequencingn/aGallardo et al. \[[@CR69]\]Chile326Index cases from families with history of BC and/or OC7.1*BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by CSGE, confirmation of the variants by direct sequencing, large rearrangement screening by MLPAMLPA panel in a subset of casesGonzalez-Hormazabal et al. \[[@CR70]\]Colombia53BC cases with FH of BC and/or OC24.5*BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by SSCP, DHPLC and PTT, confirmation of the variants by direct sequencingn/aTorres et al. \[[@CR65]\]Colombia766Unselected BC cases4.5Screening for a panel of five mutations previously observed in Colombia using restriction digestion analysisn/aTorres et al. \[[@CR34]\]Colombia96Unselected OC cases15.6Screening for a panel of 50 *BRCA1* and 46 *BRCA2* Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencingn/aRodríguez et al. \[[@CR66]\]Colombia280Unselected BC cases1.2*BRCA1* exon 11 and *BRCA2* exon 10 and 11 screening by PTT, screening for a panel of 96 recurrent Hispanic mutations by Sequenom and confirmation of the variants by direct sequencing.n/aHernandez et al. \[[@CR35]\]Costa Rica111BC cases with FH of BC4.5Screening for three founder Ashkenazi Jewish mutations using FMPA, *BRCA1* exon 11 and *BRCA2* exon 10 and 11 screening by PTT, confirmation of the variants by direct sequencingn/aGutierrez-Espeleta et al. \[[@CR58]\]Cuba307Unselected BC cases2.6Screening for three founder Ashkenazi Jewish mutations using FMPA, *BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by PTT, DGGE, and direct sequencing*BRCA1* exon 13-6 kb duplicationRodriguez et al. \[[@CR36]\]Mexico51BC cases with early onset and/or FH (BC, OC)6.3*BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by HDA, confirmation of the variants by direct sequencing.n/aRuiz-Flores et al. \[[@CR49]\]Mexico22Early onset BC cases9.1*BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by HDA, confirmation of the variants by direct sequencing.n/aCalderón-Garcidueñas et al. \[[@CR50]\]Mexico39BC and OC cases selected for early onset (BC) and/or FH (BC, OC, other BRCA associated cancers)10.2Direct sequencing (next-generation) of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsn/aVaca-Paniagua et al. \[[@CR51]\]Mexico188BC and OC cases; unselected for FH21.3Screening for a panel of 115 Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencing; Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctions for patients with negative panel resultMLPA panelVillarreal-Garza et al. \[[@CR37]\]Mexico815BC cases; unselected for FH4.3*BRCA1* exon 11 and *BRCA2* exon 10 and 11 screening by PTT, confirmation of the variants by direct sequencing; screening for a panel of 26 mutations found in Mexican*BRCA1* exon 9--12 deletionTorres-Mejia et al. \[[@CR38]\]Mexico190Triple-negative BC cases unselected for FH23.0Screening for a panel of 115 Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencing*BRCA1* exon 9--12 deletionVillarreal-Garza et al. \[[@CR37]\]Peru266BC cases; unselected4.9Screening for a panel of 115 Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencingn/aAbugattas et al. \[[@CR39]\]Puerto Rico23BC and unaffected individuals with FH (BC, OC)47.8Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsMyriad Genetics^1^Dutil et al. \[[@CR32]\]Uruguay42BC cases with FH (BC, OC)17*BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by PTT and HDA, confirmation of the variants by direct sequencingn/aDelgado et al. \[[@CR59]\]US Hispanics19Personal and/or FH suggestive of HBOC42Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsMyriad Genetics^1^Mullineaux et al. \[[@CR53]\]US Hispanics140Sibships, sisters affected with BC and/or OC and unaffected sisters0.7Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsn/aMcKean-Cowdin et al. \[[@CR54]\]US Hispanics110BC and/or OC cases; unaffected individuals with FH of BC and/or OC30.9Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsMyriad Genetics^1^ or BRCA1 exon 9--12 delWeitzel et al. \[[@CR57]\]US Hispanics393BC and/or OC cases3.5*BRCA1* only, DGGE or direct sequencing of *BRCA1* coding exons and intron/exon junctionsn/aJohn et al. \[[@CR56]\]US Hispanics78BC and/or OC cases; unaffected individuals with FH of BC and/or OC17.9Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsMyriad Genetics^1^Vogel et al. \[[@CR55]\]US Hispanics746BC and/or OC cases; unaffected individuals with FH of BC and/or OC25.3Direct sequencing of *BRCA1* and *BRCA2* coding exons and intron/exon junctionsMyriad Genetics^1^Weitzel et al. \[[@CR31]\]Venezuela58BC cases selected for early onset, bilaterality and/or FH (BC, OC, male BC).17.2Founder Jewish mutations by FMPA, *BRCA1* and *BRCA2* coding exons and intron/exon junctions screening by DGGE, confirmation of the variants by direct sequencing.n/aLara et al. \[[@CR68]\]Founder Ashkenazi Jewish mutations are *BRCA1* 185delAG, *BRCA1* 5382insC, *BRCA2* 6174delT*BC* breast cancer, *OC* ovarian cancer, *FH* family history, *SSCP* single strand conformation polymorphism, *DGGE* denaturing gradient gel electrophoresis, *PTT* protein truncation test, *HDA* heteroduplex analysis, *FMPA* fluorescent multiplexed-PCR analysis, *CSGE* conformation sensitive gel electrophoresis, *MLPA* multiplex ligation-dependent probe amplification^1^After 2002, Myriad Genetics Clinical testing includes at least a *BRCA1* 5′ rearrangement panel (exon 13 del 835 kb, exon 13 ins 6 kb, exon 22 del 510, exon 8 to 9 del 71 kb, exon 14-20 del 26 kb)

The size of the cohorts ranged from 19 to 815 individuals, the majority identified through hospital or clinic-based recruitment strategies (Table [1](#Tab1){ref-type="table"}). Several methodological factors preclude a systematic comparison across studies. There was significant variation in the inclusion criteria from unselected cases to cases selected for family history and/or personal history criteria such as age of onset and tumor molecular profile. Indirect mutation detection methods or approaches that restrict the search to panels of known mutations are expected to detect only a fraction of the variants present in the sample screened. For instance, the sensitivity of single-stranded conformation polymorphism (SSCP) ranges from 50 to 96 %, while conformation-sensitive gel electrophoresis (CSGE) and for the protein truncation test (PTT) are estimated to detect only 75 and 76 % of the *BRCA1* and *BRCA2* variants, respectively \[[@CR28]\].

Early *BRCA* testing focused on the detection of single nucleotide variants (point mutations) and small insertions or deletions rather than large genomic rearrangements. The prevalence of such rearrangement variants has been shown to vary significantly in different populations \[[@CR29]\]. Large genomic rearrangements may account for up to 21.4 % of the *BRCA* inactivating variants in high-risk patients from Latin America and the Caribbean \[[@CR30]\]. In Hispanics from the Northern California Breast Cancer Family Registry, the *BRCA1* deletion of exon 9--12 represented over 10 % of the *BRCA1* pathogenic variants identified \[[@CR31]\]. In Puerto Rico, the *BRCA2* exon 1--2 deletion is one of the three most frequent pathogenic variants, accounting for 18 % of the *BRCA* cases \[[@CR32]\]. Less than half of the studies reviewed reported screening for large scale rearrangements and only four reported performing comprehensive screening through Multiplex Ligation-dependent Probe Amplification (MLPA) (Table [1](#Tab1){ref-type="table"}). As a result of these factors, the prevalence and the diversity of the *BRCA* pathogenic variants may be underestimated in several of the published studies.

Despite those limitations, some observations stand out. In unselected breast cancer cases from Brazil \[[@CR33]\], Colombia \[[@CR34], [@CR35]\], Cuba \[[@CR36]\], Mexico \[[@CR37], [@CR38]\], and Peru \[[@CR39]\], the prevalence ranged between 1.2 and 4.9 %, which is similar to what has been reported for US non-Hispanic White populations \[[@CR40]\]. One exception is in the Bahamas, where it is estimated that 27.1 % of breast cancer cases were carriers of a *BRCA* pathogenic variant, regardless of age of onset or family history of cancers \[[@CR41], [@CR42]\].

Currently, recommendations to offer genetic testing for hereditary cancers are based on family history and/or personal history suggestive of Hereditary Breast and Ovarian Cancer. Recently, this practice has been challenged and screening every woman as part of the routine medical examination has been proposed \[[@CR43]\]. The high prevalence in the Bahamas provides an argument in favor of a more aggressive *BRCA* screening approach in such populations.

It is expected that countries for which smaller cohorts were screened show less diversity in the *BRCA* variants identified, not because they are less genetically diverse but rather as a consequence of the limitations associated with sample size in characterizing rare variants. This is exemplified by Brazil \[[@CR33], [@CR44]--[@CR48]\], Mexico \[[@CR37], [@CR38], [@CR49]--[@CR52]\], and in US Hispanics \[[@CR31], [@CR53]--[@CR57]\] where the number of different pathogenic variants detected ranged from 37 to 45 as a result of over 1300 individuals screened (Table [2](#Tab2){ref-type="table"}). Variants such as 185delAG, 5382insC, and R1443X are among the 20 most frequent *BRCA1* variants reported by the Breast Cancer Information Core (BIC) database (<http://research.nhgri.nih.gov/bic/>), and it is therefore not surprising that they are recurrent in several countries of Latin America as well. In contrast, *BRCA1* A1708E was among the 10 most frequent pathogenic variants in Latin America, observed in four different countries, but is not one of the most frequent *BRCA1* variants overall. This represents an example of a recurrent pathogenic variant specific to these populations. Interestingly, the ratio of *BRCA1* to *BRCA2* carriers also shows significant variations across Latin America. In most populations, *BRCA1* variants are more frequent than *BRCA2*, and this holds true for most countries of Latin America. However, in Costa Rica \[[@CR58]\], Cuba \[[@CR36]\], Puerto Rico \[[@CR32]\], and Uruguay \[[@CR59]\], over 80 % of the carriers had a pathogenic variant in *BRCA2*. This observation has important clinical implications as the characteristics of the cancer spectrum, and tumor pathology is expected to differ according to the gene mutated \[[@CR60]\]. For instance, *BRCA1* and *BRCA2* carriers show differences in both overall risk of developing breast and ovarian cancer and age distribution of risk \[[@CR13]\]. Cancers associated with *BRCA1* germline mutations are more frequently medullary of high mitotic counts, while *BRCA2*-associated cancers have higher score for tubule formation with lower mitotic counts \[[@CR61]\]. Compared to sporadic breast tumors, basal subtype markers are more common in tumors arising in *BRCA1* carriers \[[@CR62]\] but not in *BRCA2* carriers \[[@CR63]\]. In contrast, *BRCA2*-associated tumors are more likely to be of the luminal subtype and estrogen receptor positive when compared to controls \[[@CR64]\].Table 2Recurrent *BRCA1* and *BRCA2* mutations in Latin America, the Caribbean, and US HispanicsCountryIndividuals screened *n*Carriers *n*Mutations *n*Recurrent mutations^1^ *n*Carriers with a recurrent mutation *n* (%)Argentina94191900Argentina (Ashkenazi Jews)40173317 (100)Bahamas2044711642 (89.4)Brazil14088237954 (65.9)Chile38040181230 (75.0)Colombia11956310356 (88.9)Costa Rica1115412 (40.0)Cuba3077612 (28.6)Mexico13051284515101 (78.9)Peru266135311 (84.6)Puerto Rico2311638 (72.7)Uruguay426600US Hispanics14861734117149 (86.1)Venezuela589812 (22.2)^1^For any given country, a recurrent mutation is defined as a mutation identified in more than one unrelated *BRCA* carriers

In some countries, a few recurrent variants explain the majority of cases linked to *BRCA*-inactivation. As a result, a PCR-based MassARRAY (Sequenom) panel of recurrent mutations, the HISPANEL, was developed in the US and validated among US Hispanic and Mexican populations. Compared with direct sequencing, this approach was estimated to have a sensitivity of 68 % but for a fraction of the cost, which is an important factor to consider in countries where resources are limited. Such an approach could be considered for Colombia where despite having identified 63 carriers in 1195 individuals screened, three recurrent variants explained over 88 % of the cases \[[@CR34], [@CR35], [@CR65], [@CR66]\]. On the other hand, this strategy may not be adequate for countries such Argentina \[[@CR67]\], Uruguay \[[@CR59]\], and Venezuela \[[@CR68]\] where most recurrent pathogenic variants are not frequent. (Table [2](#Tab2){ref-type="table"}).

In addition, the question remains whether this panel could be transferable from one country to another. The E1308X variant is the most frequent in Puerto Rico and has been observed in the US but has not been observed in any other countries of Latin America. Within Latin America, only 8.02 % (*n* = 13) of the pathogenic variants reported were present in two or more countries. Caution should also be taken in studying US Hispanic to make inferences about the populations of origin of these immigrants. The *BRCA2* 6174delT variant was one of the most frequently observed in Latin America (except for Mexico) but has still not been reported in US Hispanics. Many of the recurrent variants found in Chile \[[@CR69], [@CR70]\] have not been observed in US Hispanics. Overall, of the 167 *BRCA* pathogenic variants identified in this literature review, only 10.4 % (*n* = 17) were shared between US Hispanics and Latin America. While these observations may be the result of the limited sample sizes available for some of the countries, it suggests that the Latin America immigrants established in the US might not represent the genetics of their populations of origin in their complexity. It is also a reflection of the demographics of the US Hispanic populations, where countries like Mexico and Puerto Rico are overrepresented. As illustrated by the network of interaction of recurrent *BRCA* variants between the Latin America countries (Fig. [1](#Fig1){ref-type="fig"}), it can be observed that the most frequent variants are more likely to be shared across countries, but a significant number of recurrent variants are found in one country only. Therefore, the available data, even though limited, suggest that the development of a low-cost Latin American screening panel that would be widely offered is unlikely as a result of the limited overlap in the spectrum of reported *BRCA1* and *BRCA2* variants in Latin America and US Hispanics.Fig. 1The network of recurrent *BRCA1* (**a**) and *BRCA2* (**b**) pathogenic variants reported in Latin America, the Caribbean, and US Latinos. Recurrent variants have been reported more than once within a country and/or have been observed in more than one country. The connections between the nodes generate a complete system of interactions between variants and the countries in which they have been detected. The nodes representing the countries are mapped on the network based on the proportion of shared variants with other Latin America countries. The size of the nodes representing the variants is proportional to the total number of observations, dashed edges were used for recurrent variants that were unique to a country, and thicker edges indicate variants that are shared in more countries. The blue node colors indicate countries for which at least one study conducted comprehensive *BRCA1*/*2* analysis by direct sequencing, and the green nodes indicate countries for which *BRCA* analysis was conducted using mutation panels or indirect analysis methods. Darker nodes (*dark blue* or *dark green*) indicate countries for which at least one study conducted comprehensive large rearrangement screening, while the pale node colors (*pale blue* or *pale green*) indicate countries for which no comprehensive rearrangements were assessed. The network was generated with Cytoscape 3.2.1 \[[@CR96]\]

Population history shaped the *BRCA* variant spectrum in Latin America {#Sec3}
----------------------------------------------------------------------

The genetic makeup of modern populations in Latin America is a combination of pre-Colombian and colonial heritage, both in the diversity of the gene pools imported in the Americas and their subsequent admixture. Accordingly, heterogeneity in admixture patterns has been shown to vary significantly across and within the continent \[[@CR71]--[@CR76]\]. From the 15th century, the European colonial migration to the New World nearly decimated the Native American populations \[[@CR77]\]. European founders were mainly of Spanish and Portuguese origin but also reflected the diversity of the Iberian peninsula \[[@CR71]\]. During the Atlantic trade between 1451 and 1870, an estimated nine million slaves were brought to the Americas from the West Coast of Africa \[[@CR78]\]. In the context of testing for hereditary cancer predisposition variants, data from the 1000 Genomes Consortium demonstrated that rare variants are more likely to be specific to a continent or country than common variants \[[@CR79]\], suggesting that one should account for the diversity of the populations inhabiting Latin America when designing screening and prevention strategies.

Some recurrent pathogenic variants in the populations from Latin America can be associated with documented migration events. The origin of the Jewish pathogenic variant *BRCA1* 185delAG can be traced back to 1492 when, coinciding with the start of the colonization of the Americas, Jews were forced to convert or be expelled from the Iberian Peninsula. In the view of the long-lasting genetic admixture of Sephardic and Ashkenazi Jews, and following migration of Jews into the countries of South and North America, it is not surprising that typical founder Jewish mutations are commonly found in the modern Argentina, Peru, Brazil, Chile, and US Hispanics. In some cases, haplotype analysis has confirmed that the origin of the 185delAG in populations from Latin America was in fact the same as the Jewish founder mutation \[[@CR57]\].

Fewer recurrent variants are traced back to the African continent, despite a significant contribution of African ancestry to the genetic pool of some of the populations of Latin America. Among the factors proposed to explain, this observation is the exceptional genetic diversity both within Africa and in the numerous ethnic groups that were brought to the Americas during the Atlantic slave trade. One exception is the *BRCA1* 943ins10 mutation, which is the most frequently pathogenic variant reported in African-Americans by Myriad Genetics Laboratories, representing 10 % of the 279 African-American *BRCA* pathogenic variants \[[@CR80]\]. The presence of a single haplotype in families from the Ivory Coast, Florida, Southeastern US, and the Bahamas is consistent with a founder effect originating in West Africa \[[@CR81]\].

Taken together, these examples indicate that the mutation spectrum of each Latin American population is expected to be strongly linked to their migration history. Hence, one could extrapolate that the extent of the overlap in the frequent *BRCA* mutations observed between countries will be, at least in part, determined by the shared events and interchanges that characterize the migration history of each geographical region. The *BRCA1* deletion of exons 9--12 is a recurrent pathogenic variant observed in unrelated families of Mexican origin, which are geographically dispersed in the US \[[@CR31], [@CR82]\]. Haplotype analysis pointed to a founder effect of a variant that would have originated in Amerindian or Mestizo populations \[[@CR82]\]. Other examples include a *BRCA1* 3450del4 identified in multiple breast and ovarian cancer patients from Brazil \[[@CR45], [@CR47]\], Chile \[[@CR70]\], and Colombia \[[@CR34], [@CR35], [@CR65], [@CR66]\], which is also common in breast cancer populations from Spain \[[@CR83]\] and Portugal \[[@CR84]\]. In contrast, the *BRCA1* 5382insC founder pathogenic variant is most frequently reported in Brazil by several independent studies \[[@CR33], [@CR44], [@CR45], [@CR48]\] but has not been observed elsewhere in South America with the exception of an Ashkenazi community in Argentina \[[@CR67]\]. This indicates that the genetic background of the Latin American populations is also shaped by events leading to unique population structures within and between countries.

Caution should be taken when making inferences about the origin of *BRCA* variants based solely on the co-occurrence in two populations. In the absence of haplotype analysis, one cannot distinguish whether a variant has migrated from one historically linked geographic area to another or is the result of independent mutational events. Therefore, not all carriers of the recurrent pathogenic variants or well-known founder mutations are expected to share a common ancestor. For example, *BRCA2* 3034del4 is a recurrent variant, which was also observed as a de novo germline mutation in a case of early onset breast cancer with no strong family history of cancer \[[@CR85]\]. In families of Northern Europe Caucasian ancestry, this same mutation was observed in seven different countries and showed considerable haplotype diversity \[[@CR86]\]. Haplotype analyses have identified multiple origins for several other recurrent mutations, including *BRCA1* 185delAG \[[@CR87]\]. This suggests that some regions of the *BRCA1* and *BRCA2* genes might be prone to mutations. It is also noteworthy in light of the small proportion of studies who conduct mutation screening in the context of haplotype analysis. Finally, de novo variants may also be underreported as the majority of individuals undergoing *BRCA* testing are selected for having strong family history of cancer.

Cancer genetic testing awareness and access in Latin American populations {#Sec4}
-------------------------------------------------------------------------

While hereditary clinical testing of Latin American and US Hispanic populations could greatly benefit from a better understanding of the mutation spectrum in the *BRCA* genes, social-economic aspects of genetic testing will also need to be addressed to improve access. In its policy statement on genetic and genomic testing, ASCO emphasizes the role of the informed consent process and recommends that cancer genetic susceptibility testing be conducted in the context of pre- and post-testing genetic counseling \[[@CR88]\]. Positive outcomes associated with testing may be limited in the absence of genetic counseling and integrated clinical management structure ensuring that carriers are engaged in appropriate screening and prevention programs. Given that Hispanics in the US are 1.8 times more likely to receive an inconclusive result (variant of uncertain significance) \[[@CR80]\], the participation of genetics professionals pre- and post-testing becomes especially important to provide support to the patients and physicians. Finally, a negative test results in the absence of a known mutation in the family may provide a false reassurance, especially when testing is not conducted in the context of extended panels of genes \[[@CR89]\].

Studies reporting on awareness and access to genetic testing in Latin America are sparse, but the situation in the US has been more documented. In a cross-sectional analysis of 46,276 women who underwent *BRCA* genetic testing between 1996 and 2006, only 4.2 % were of Latin American ethnicity \[[@CR80]\]. In a US sample of 1414 women diagnosed with breast cancer at or before 40 years of age between 2004 and 2007, Hispanic women were significantly less likely to be tested for *BRCA1* and *BRCA2* mutations \[[@CR90]\]. This disparity in access to cancer genetic testing is especially alarming knowing that the Hispanic population accounts for approximately 16.3 % of the US population \[[@CR21]\]. Genetic testing awareness has been shown to be significantly lower in Hispanics of the US when compared to non-Hispanic whites \[[@CR91]\]. Acculturation, especially the use of the English language, strongly correlated with awareness of genetic testing for cancer in the US \[[@CR92]\]. Once informed, participants held favorable attitudes toward risk assessment and counseling \[[@CR93], [@CR94]\]. In some parts of Latin America, limited resources both monetary and in the availability of trained genetic professional may impede accessibility to cancer genetic testing. Recently, *BRCA1*/*2* telephone counseling was shown to be as effective in providing psychological support and guiding informed decisions \[[@CR95]\]. This might contribute to improve access to genetic counseling in Latin American, especially in rural setting.

Conclusions {#Sec5}
===========

Therefore, for the populations of Latin America and US Hispanics to benefit from genetic-based cancer prevention options, a strategy that combines acquiring a better knowledge of the variants underlying hereditary cancers in those population and improved access to genetic testing will need to be developed. From the data available, the following recommendations emerge: (1) If panels of mutation are the only economically feasible approach, they should be developed after comprehensive analysis of a large series of samples rather than testing panels that have been developed from other populations; (2) large genomic rearrangements should be included; and (3) proper clinical infrastructure including genetic counseling should be widely available.
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Protocol for the identification and selection of the studies to be included. Pubmed database was searched for combination of the following MeSH terms: "Genes, *BRCA1*" or "Genes, *BRCA2*" and "South America" or "Central America" or "Caribbean Region" or "Hispanic Americans" or "Mexico" and "Mutation" or "Hereditary Breast and Ovarian Cancer Syndrome". Please note that Mexico was searched separately as it is not listed as a sub-category of "Central America" MeSH term. A total of 48 studies were identified through that search, out of which 21 met the eligibility criteria. Reasons for excluding a study included 1) no mutations identified in the sample analyzed (*n* = 4), sample analyzed is the same as another study already included (*n* = 2), gene analyzed is other than *BRCA1* or *BRCA2* (*n* = 1), full text not available online (*n* = 1), study population is not from Latin America, Brazil or US Hispanic (*n* = 1), study does not conduct mutation analysis of *BRCA1* and *BRCA2* (*n* = 10). The literature cited from selected papers was systematically searched and additional eligible studies were identified (*n* = 11). A total of 33 eligible studies were included in the analysis. Supplementary material 1 (JPEG 83 kb)

###### 

Nomenclature of the pathogenic variants identified in US Hispanics, Latin America and the Caribbean. Designations from the Breast Cancer Information Core (BIC, https://research.nhgri.nih.gov/projects/bic/Member/index.shtml), Human Genome Variation Society (HGVS, http://www.hgvs.org/), the single nucleotide polymorphisms database (dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/) and the Breast ExAC Exome Aggregation Consortium (http://exac.broadinstitute.org/) are provided. The total number of times and the countries where each mutation was reported is listed for each variant. *NR* not reported, *N/a* not applicable. Supplementary material 2 (XLSX 27 kb)
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